A groundbreaking study reveals that the new RSV drug, nirsevimab, boasts a 93% success rate in preventing RSV-related hospitalizations in young children. While the drug’s real-world impact is currently limited by low usage, researchers predict a substantial public health benefit with wider adoption.
GSK’s Arexvy RSV vaccine, currently approved for adults 60 and older, shows positive preliminary data in adults aged 18-49 at increased risk for respiratory illness, potentially broadening its reach to a larger population. This development comes as both GSK and Pfizer face declining sales due to narrow age recommendations for their RSV vaccines.
The FDA has expanded the use of Pfizer’s Abrysvo RSV vaccine, now offering protection to adults aged 18-59 at high risk for respiratory illness. This move broadens the vaccine’s reach, providing a vital safeguard against RSV for a larger population, including pregnant women who can protect their infants. The decision is based on the success of the MONeT study, highlighting the vaccine’s safety and effectiveness. The approval comes as RSV vaccine sales have declined following regulatory adjustments, underscoring the crucial role Abrysvo plays in building new revenue streams for Pfizer.
